Singhal Priya's Insider Trades & SAST Disclosures
Singhal Priya's most recent trade in Biogen Inc was a trade of 1,212 Common Stock done . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Singhal Priya.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 1,212 | 9,423 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 1,212 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.54 per share. | 10 Feb 2025 | 357 | 9,066 (0%) | 0% | 142.5 | 50,887 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 14,050 | 14,050 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 2,216 | 4,434 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 2,216 | 8,892 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 681 | 8,211 (0%) | 0% | 141.3 | 96,259 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,828 | 7,254 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,828 | 1,829 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.93 per share. | 31 Jan 2025 | 578 | 6,676 (0%) | 0% | 143.9 | 83,192 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 426 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 426 | 5,742 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.78 per share. | 06 Dec 2024 | 206 | 5,536 (0%) | 0% | 157.8 | 32,503 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 157.21 per share. | 06 Dec 2024 | 110 | 5,426 (0%) | 0% | 157.2 | 17,293 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 1,668 | 1,669 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 1,668 | 6,554 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 204.76 per share. | 30 Aug 2024 | 807 | 5,747 (0%) | 0% | 204.8 | 165,241 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 204.22 per share. | 30 Aug 2024 | 431 | 5,316 (0%) | 0% | 204.2 | 88,019 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 213.09 per share. | 02 Apr 2024 | 93 | 4,886 (0%) | 0% | 213.1 | 19,817 | Common Stock |
| Biogen Inc | Singhal Priya | Head of Development | Sale of securities on an exchange or to another person at price $ 221.23 per share. | 22 Feb 2024 | 262 | 4,886 (0%) | 0% | 221.2 | 57,962 | Common Stock |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 819 | 0 | - | - | Performance Stock Unit | |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 819 | 5,335 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Other type of transaction at price $ 0.00 per share. | 16 Feb 2024 | 485 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 389 | 485 | - | - | Restricted Stock Unit | |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 389 | 5,429 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Singhal Priya | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 295 | 5,040 (0%) | 0% | 219.1 | 64,629 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 173 | 5,256 (0%) | 0% | 219.1 | 37,901 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 221.49 per share. | 16 Feb 2024 | 108 | 5,148 (0%) | 0% | 221.5 | 23,921 | Common Stock |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 1,212 | 1,212 | - | - | Restricted Stock Unit | |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 1,212 | 5,309 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 239.45 per share. | 09 Feb 2024 | 419 | 4,516 (0%) | 0% | 239.5 | 100,330 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.98 per share. | 09 Feb 2024 | 374 | 4,935 (0%) | 0% | 241.0 | 90,127 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 6,650 | 6,650 | - | - | Restricted Stock Unit | |
| Biogen Inc | Singhal Priya | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 1,828 | 3,657 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 1,828 | 5,292 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 245.93 per share. | 01 Feb 2024 | 634 | 4,097 (0%) | 0% | 245.9 | 155,920 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.83 per share. | 01 Feb 2024 | 561 | 4,731 (0%) | 0% | 247.8 | 139,033 | Common Stock |
| Biogen Inc | Singhal Priya | Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 819 | 819 | - | - | Performance Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2023 | 426 | 3,780 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2023 | 426 | 426 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.29 per share. | 08 Dec 2023 | 206 | 3,574 (0%) | 0% | 239.3 | 49,294 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 248.00 per share. | 08 Dec 2023 | 110 | 3,464 (0%) | 0% | 248 | 27,280 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 315 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 315 | 3,158 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 284.85 per share. | 30 Jun 2023 | 153 | 3,005 (0%) | 0% | 284.8 | 43,582 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 282.86 per share. | 30 Jun 2023 | 81 | 2,924 (0%) | 0% | 282.9 | 22,912 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 277.11 per share. | 04 Apr 2023 | 91 | 2,843 (0%) | 0% | 277.1 | 25,217 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 270.06 per share. | 28 Mar 2023 | 568 | 2,842 (0%) | 0% | 270.1 | 153,394 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.75 per share. | 02 Mar 2023 | 543 | 3,257 (0%) | 0% | 268.7 | 145,931 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Other type of transaction at price $ 0.00 per share. | 02 Mar 2023 | 341 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 297 | 341 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 297 | 3,554 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.75 per share. | 02 Mar 2023 | 144 | 3,410 (0%) | 0% | 268.8 | 38,700 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 460 | 3,951 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 460 | 1,282 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Other type of transaction at price $ 0.00 per share. | 17 Feb 2023 | 408 | 874 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.38 per share. | 17 Feb 2023 | 151 | 3,800 (0%) | 0% | 278.4 | 42,035 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,211 | 2,424 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,211 | 3,863 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 372 | 3,491 (0%) | 0% | 286.3 | 106,504 | Common Stock |
| Biogen Inc | Priya Singhal | Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 5,485 | 5,485 | - | - | Restricted Stock Unit | |
| Biogen Inc | Priya Singhal | Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 1,123 | 2,652 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges